LIPOSOMAL AMPHOTERICIN B (L-AMB) TWICE WEEKLY AS ANTIFUNGAL PROPHYLAXIS IN PEDIACTRIC CANCER PATIENTS

被引：0

作者：

Lehrnbecher, Thomas ^{[1
]}

Schedler, Nadine ^{[1
]}

Tramsen, Lars ^{[1
]}

Becker, Martina ^{[1
]}

Klingebiel, Thomas ^{[1
]}

Bochennek, Konrad ^{[1
]}

机构：

[1] Goethe Univ Frankfurt, Frankfurt, Germany

来源：

PEDIATRIC BLOOD & CANCER | 2010年 / 55卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：948 / 949

页数：2

共 50 条

[11] A randomized phase III trial of low dose liposomal amphotericin B (L-AmB) as prophylaxis of invasive fungal infections (IFI) in neutropenic patients (pts).
Penack, O
Schwartz, S
Martus, P
Reinwald, M
Schmidt-Hieber, M
Thiel, E
Blau, IW
BLOOD, 2005, 106 (11) : 28A - 28A
[12] Secondary antifungal prophylaxis with liposomal amphotericin B (AmB-L) in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT)
Busca, Alessandro
D'Ardia, Stefano
Terruzzi, Elisabetta
Pogliani, Enrico
Alessandrino, Emilio Paolo
Griva, Vassiliki
Deliliers, Giorio Lambertenghi
BLOOD, 2007, 110 (11) : 320B - 320B
[13] Pharmacokinetic evaluation of liposomal amphotericin B (L-AMB) in patients with invasive fungal infection: Population approach in Japanese pediatrics
Ohata, Yuka
Tomita, Yoshiko
Suzuki, Kota
Maniwa, Takashi
Yano, Yoshitaka
Sunakawa, Keisuke
DRUG METABOLISM AND PHARMACOKINETICS, 2015, 30 (06) : 400 - 409
[14] Safety and Tolerability of High-dose Weekly Liposomal Amphotericin B Antifungal Prophylaxis
Hand, Elizabeth O.
Ramanathan, Meenakshi R.
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (08) : 835 - 836
[15] Empirical antifungal therapy (Rx) with caspofungin (CAS) vs liposomal amphotericin B (L-AmB) for persistently febrile neutropenic patients (pts) with acute myeloid leukemia (AML).
Maertens, JA
Teppler, H
Lupinacci, R
Bourque, M
DiNubile, M
Sable, C
BLOOD, 2004, 104 (11) : 376A - 376A
[16] Liposomal amphotericin B as antifungal prophylaxis in bone marrow transplant patients
Falagas, ME
Vardakas, KZ
AMERICAN JOURNAL OF HEMATOLOGY, 2006, 81 (04) : 299 - 300
[17] Liposomal amphotericin B (L-AMB) is superior to amphotericin B deoxycholate (AmB-d) in preventing breakthrough fungal infections in patients with prolonged neutropenia and fever: Results of a sub-group analysis of an empirical antifungal therapy trial.
Cordonnier, C
Walsh, TJ
Bresnik, M
BLOOD, 2004, 104 (11) : 376A - 376A
[18] Cost-Efficacy analysis of Liposomal Amphotericin B (L-AmB) versus Amphotericin B Lipid Complex (ABLC) in the empirical treatment of febrile neutropenia
Eandi, Mario
FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2005, 6 (04) : 333 - 347
[19] Improved safety and efficacy of AmBisome (liposomal amphotericin B, L-AmB) vs. amphotericin B (CAB) in the empirical treatment of febrile neutropenic patients undergoing BMT.
Cagnoni, PJ
Grethlein, S
Korones, DN
Goldman, M
Kaizer, H
BONE MARROW TRANSPLANTATION, 1999, 23 : S112 - S112
[20] Could liposomal amphotericin B (L-AMB) lock solutions be useful to inhibit Candida spp. biofilms on silicone biomaterials?
Toulet, Delphine
Debarre, Cecile
Imbert, Christine
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (02) : 430 - 432

← 1 2 3 4 5 →